Medical Condition News

RSS

Menu labeling at chain restaurants has some benefits

The recent Supreme Court decision on the Patient Protection and Affordable Care Act has cleared the way for national requirements about posting nutritional information at chain restaurants. Listing calories, fat content, and sodium levels of menu items at the point of purchase has been promoted as a way to address the obesity epidemic.

21 Jul 2012

Training EMS to interpret ECGs can expedite treatment for severe heart attacks

A new program that trains emergency medical service technicians (EMS) to read electrocardiograms so that they can evaluate patients with chest pain, and expedite treatment for the severe heart condition known as ST-segment elevation myocardial infarction (STEMI), a serious form of heart attack, has excellent results and should become the standard of care, according to two studies published in the current issue of the Canadian Journal of Cardiology.

21 Jul 2012

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Axial lumbar interbody fusion for two spinal levels may not be effective

Surgeons from the Instituto de Patologia da Coluna in Sao Paulo, Brazil have found that an innovative minimally invasive surgical procedure performed to achieve two-level axial lumbar interbody fusion produced immediate successful results, but within 2 years complications set in, making the procedure far less desirable.

21 Jul 2012

2-D models may often give researchers misleading results

Imagine millions of cancer cells organized in thousands of small divots. Hit these cells with drugs and when some cells die, you have a candidate for a cancer drug. But a review published this week in the journal Expert Opinion on Drug Discovery argues that these 2D models in fact offer very little information about a potential drug's effects in the body and may often give researchers misleading results.

21 Jul 2012

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

Millennium: The Takeda Oncology Company and, Takeda Pharmaceutical Company Limited today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for conditional approval of brentuximab vedotin for two indications.

21 Jul 2012

Second Sight’s Argus II Retinal Prosthesis System scheduled for FDA panel review

Second Sight Medical Products Inc., the world's leading developer and manufacturer of retinal prostheses, today announced that a U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel has been scheduled to review the data presented in the company's Humanitarian Device Exemption (HDE) market approval application for its Argus II Retinal Prosthesis System (Argus II prosthesis) on September 28, 2012 in Gaithersburg, Maryland.

21 Jul 2012

Neuroscience 2012 annual meeting to take place from Oct. 13-17

Neuroscience 2012, the annual meeting of the Society for Neuroscience, is the world's largest source of emerging news on brain science and health. Learn how the brain works and new developments on a range of topics: aging, language, brain injury, parenting, and mental illness, among others. More than 16,000 new discoveries will be presented, with 30,000 attendees from around the world.

21 Jul 2012

Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

Janssen-Cilag International NV announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of DACOGEN (decitabine) for Injection.

21 Jul 2012

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

Pfizer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU), for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

21 Jul 2012

New antibody can be used as early diagnostic tool for Parkinson's

Conditions such as Parkinson's disease are a result of pathogenic changes to proteins. In the neurodegenerative condition of Parkinson's disease, which is currently incurable, the alpha-synuclein protein changes and becomes pathological. Until now, there have not been any antibodies that could help to demonstrate the change in alpha-synuclein associated with the disease. An international team of experts led by Gabor G. Kovacs from the Clinical Institute of Neurology at the MedUni Vienna has now discovered a new antibody that actually possesses this ability.

21 Jul 2012

Number of blind persons decline in Germany

The numbers of people in Germany who are blind or visually impaired is going down. Robert P. Finger and his co-authors present their findings in the current edition of Deutsches -rzteblatt International.

21 Jul 2012

CBT, pharmacologic interventions decrease depressive symptoms in cancer patients

Despite guidelines recommending screening for depression in cancer patients, it's been unclear whether interventions designed to treat this depression are effective. A study by the University of Colorado Cancer Center and other institutions, published in the Journal of the National Cancer Institute, changes that.

21 Jul 2012

Marshall University faculty member receives $426,000 NIH grant for lung cancer study

A Marshall University faculty member has been awarded a three-year, $426,000 grant by the National Institutes of Health (NIH) to further her lung cancer research.

21 Jul 2012

Study explores role of L. reuteri against foodborne infection

While many bacteria exist as aggressive pathogens, causing diseases ranging from tuberculosis and cholera, to plague, diphtheria and toxic shock syndrome, others play a less malevolent role and some are critical for human health.

21 Jul 2012

RPB awards $110,000 grant to Mass. Eye and Ear and HMS for research into blinding diseases

Research to Prevent Blindness (RPB) has awarded a grant of $110,000 to the Massachusetts Eye and Ear Infirmary to support research into the causes, treatment and prevention of blinding diseases. The research will be directed by Joan W. Miller, M.D., Chief of the Mass. Eye and Ear and Mass. General Hospital's Departments of Ophthalmology and Chair of the Department of Ophthalmology at Harvard Medical School.

21 Jul 2012

HPV positively impacts overall survival in African Americans with oropharyngeal cancer

Even though the human papillomavirus (HPV) is a risk factor for certain head and neck cancers, its presence could make all the difference in terms of survival, especially for African Americans with throat cancer, say Henry Ford Hospital researchers.

21 Jul 2012

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

Sanofi and Regeneron Pharmaceuticals, Inc. announced today that several trials within ODYSSEY, the Phase 3 clinical program of SAR236553/REGN727, have initiated patient enrollment.

21 Jul 2012

uniQure receives positive recommendation from EMA CHMP for Glybera

uniQure announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion that recommends marketing authorization of Glybera (alipogene tiparvovec) as a treatment for lipoprotein lipase deficiency (LPLD) under exceptional circumstances.

21 Jul 2012

Medical Condition News

Menu labeling at chain restaurants has some benefits

Training EMS to interpret ECGs can expedite treatment for severe heart attacks

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Axial lumbar interbody fusion for two spinal levels may not be effective

2-D models may often give researchers misleading results

EMA CHMP issues positive opinion for conditional approval of brentuximab vedotin for lymphoma

Second Sight’s Argus II Retinal Prosthesis System scheduled for FDA panel review

Neuroscience 2012 annual meeting to take place from Oct. 13-17

Janssen-Cilag receives positive opinion from EMA CHMP for DACOGEN

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

New antibody can be used as early diagnostic tool for Parkinson's

Number of blind persons decline in Germany

CBT, pharmacologic interventions decrease depressive symptoms in cancer patients

Marshall University faculty member receives $426,000 NIH grant for lung cancer study

Study explores role of L. reuteri against foodborne infection

RPB awards $110,000 grant to Mass. Eye and Ear and HMS for research into blinding diseases

HPV positively impacts overall survival in African Americans with oropharyngeal cancer

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Regeneron, Sanofi initiate enrollment in SAR236553/REGN727 Phase 3 program

uniQure receives positive recommendation from EMA CHMP for Glybera

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News